证券代码：300534 证券简称：陇神戎发 公告编号：2023-086 甘肃陇神戎发药业股份有限公司 关于控股子公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据全国高新技术企业认定管理工作领导小组办公室于 2023 年 11 月 7 日发 布的《关于对甘肃省认定机构 2023 年认定报备的第二批高新技术企业进行备案 的公告》，甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘 肃普安制药股份有限公司（以下简称"普安制药"）通过了高新技术企业重新认 定，证书编号为 GR202362000442，发证日期为 2023 年 10 月 16 日。 本次高新技术企业的认定系普安制药原高新技术企业证书有效期满后所进 行的重新认定，根据国家对高新技术企业的相关税收政策规定，普安制药自通过 高新技术企业认定起连续三年可继续享受国家关于高新技术企业的相关税收优 惠政策，即按 15%的税率缴纳企业所得税。 甘肃陇神戎发药业股份有限公司 董事会 2023 年 11 月 8 日 普安制药再次通过国家高新技术企业认定，是对企业技术实力、 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2023-085 甘肃陇神戎发药业股份有限公司 关于收到控股子公司业绩承诺补偿款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）于 2019 年 5 月以现金 方式收购自然人王青川、宋学梅（以下简称"交易对方"或"业绩承诺方"）所 持有的兰州三元药业有限责任公司（现名称：甘肃药业集团三元医药有限公司， 以下简称"三元医药"）51%股权，根据公司与上述交易对方签订的《王青川、宋 学梅与甘肃陇神戎发药业股份有限公司之间关于兰州三元药业有限责任公司之 股权转让协议》和《王青川、宋学梅与甘肃陇神戎发药业股份有限公司之间关于 兰州三元药业有限责任公司之股权转让协议之补充协议》（以下简称"《股权转让 协议》和《股权转让协议之补充协议》"），交易对方承诺三元医药在 2019 年度至 2021 年度（即业绩承诺期），完成主营业务收入分别为不低于 6,000.00 万元、 8,000.00 万元、10,000.00 万元，实现的净利润分别不低于 600.00 万元、80 ...

Financial Performance - Revenue for Q3 2023 reached ¥220,834,019.31, a 77.19% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥14,634,388.27, reflecting a 91.87% year-over-year growth[5] - The company reported a basic earnings per share of ¥0.0482, up 92.03% from the previous year[5] - The total operating revenue for the third quarter of 2023 reached CNY 812,306,262.81, a significant increase from CNY 401,104,308.02 in the same period last year, representing a growth of approximately 102.5%[27] - The net profit for the third quarter of 2023 reached CNY 62,932,999.22, a significant increase from CNY 19,056,957.67 in the same period last year, representing a growth of approximately 230.5%[28] - Operating profit for the third quarter was CNY 74,610,054.50, compared to CNY 24,580,944.93 in the previous year, indicating an increase of about 203.5%[28] - The company’s basic and diluted earnings per share for the third quarter were both CNY 0.1544, compared to CNY 0.0528 in the same quarter last year, representing an increase of approximately 192.3%[29] - Total comprehensive income for the third quarter was CNY 62,932,999.22, compared to CNY 19,056,957.67 in the previous year, reflecting a growth of about 230.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,323,425,482.21, an increase of 1.65% from the end of the previous year[5] - The total assets of the company as of September 30, 2023, amounted to CNY 1,323,425,482.21, up from CNY 1,301,901,629.42 at the beginning of the year, reflecting a growth of about 1.6%[25] - Total liabilities increased to CNY 635,850,419.50 from CNY 421,620,965.93, indicating a rise of approximately 50.8%[25] - The company's equity attributable to shareholders decreased to CNY 616,774,145.06 from CNY 827,265,085.07, representing a decline of about 25.5%[25] Cash Flow - The company’s operating cash flow net amount for the year-to-date was ¥38,433,800, a 49.33% increase compared to the same period last year[5] - The net cash flow from operating activities increased by 49.33% year-on-year, driven by higher cash receipts from sales of goods and services[12] - The company reported cash inflows from operating activities of CNY 856,953,891.22, compared to CNY 499,251,667.85 in the previous year, marking a growth of about 71.8%[30] - Cash outflows from operating activities totaled CNY 818,520,001.01, up from CNY 473,514,617.29, resulting in a net cash flow from operating activities of CNY 38,433,890.21, an increase of 49.0% year-over-year[31] - The company’s cash and cash equivalents decreased to CNY 263,444,470.55 as of September 30, 2023, down from CNY 369,244,036.02 at the beginning of the year, reflecting a decline of approximately 28.6%[22] - The company’s cash and cash equivalents at the end of the period were CNY 263,444,470.55, compared to CNY 134,756,366.82 at the end of the previous year, indicating an increase of approximately 95.1%[31] Expenses and Investments - The company’s sales expenses increased by 162.72% year-over-year, primarily due to increased market expansion costs[11] - The company’s investment income decreased by 100%, indicating a reduction in investment returns during the reporting period[11] - Research and development expenses rose to CNY 20,650,952.75, up from CNY 16,256,471.85, reflecting a year-over-year increase of approximately 27.5%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,996[14] - Gansu Pharmaceutical Investment Group Co., Ltd. holds 29.93% of the shares, making it the largest shareholder[14] Corporate Developments - The company obtained a drug re-registration approval notice for the product "Mahuang Xingren Zhike Jiao Nang" on January 5, 2023[15] - The company completed the acquisition of Gansu Puan Pharmaceutical Co., Ltd. on February 8, 2023, with the transfer of 70% of the shares[16] - The company appointed Qian Shuangxi as the new general manager on March 10, 2023[18] - The company appointed Zhao Zhengcai as the new Vice President and Chief Financial Officer following the resignation of Liu Maosheng[19] - The company’s subsidiary, Gansu Puan Pharmaceutical Co., Ltd., underwent a change in legal representative and obtained new licenses, indicating ongoing operational adjustments and compliance efforts[20] - The company expanded its production line for "Hefei" and obtained a new production license on February 15, 2023[17] Inventory and Borrowings - Inventory increased by 47.73% compared to the beginning of the period, as the company ramped up production to ensure supply during peak sales[9] - Short-term borrowings doubled, reflecting a new ¥30 million loan for working capital[9]

证券代码：300534 证券简称：陇神戎发 公告编号：2023-082 甘肃陇神戎发药业股份有限公司 关于同一控制下国有股权转让的进展公告 三、本次股权转让对公司的影响及后续事项 本次国有股权转让系同一控制下不同主体之间的协议转让，不会导致公司控 股股东、实际控制人发生变更，对公司持续经营能力、损益及资产状况均无重大 影响。 甘肃陇神戎发药业股份有限公司（以下简称"陇神戎发"、"公司"）于 2023 年 6 月 5 日收到国有股东甘肃生物产业创业投资基金有限公司（以下简称"生物 基金"）《关于陇神戎发股权协议转让的告知函》，根据生物基金股东会决议、甘 肃兴陇资本管理有限公司（以下简称"兴陇资本"）股东决定，生物基金根据基 金清算和项目退出的需要，决定将生物基金持有的陇神戎发 7.11%股权 （21,575,777 股）以协议转让方式转让给兴陇资本。 本次国有股权转让实施完成后，生物基金不再持有陇神戎发股份，兴陇资本 将持有陇神戎发 7.11%股权（21,575,777 股）。公司直接控股股东甘肃药业投资 集团有限公司持有陇神戎发股份比例及数量保持不变，公司间接控股股东甘肃省 国有资产投资集团有限公司直接及间接 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2023-081 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品经营许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃药业 集团三元医药有限公司（以下简称"三元医药"）因其《药品经营许可证》有效 期即将届满而申请换证，于近日收到由甘肃省药品监督管理局换发后的新证，现 将有关情况公告如下： 一、换发后的《药品经营许可证》基本信息 企业名称：甘肃药业集团三元医药有限公司 有效期至：2028 年 09 月 18 日 许可证编号：甘 AA931H693 社会信用代码：91620102MA73LG7052 注册地址：甘肃省兰州市城关区张掖路街道延寿巷 8 号 1 单元 6 层 004 号-4 法定代表人（负责人）：王青川 企业负责人：王青川 质量负责人：魏萍 经营范围：中药材(国限品种除外)、中药饮片、中成药、化学原料药、抗生 素原料药、抗生素制剂、化学药制剂、生物制品(除疫苗)*** 经营方式：批发（法人） 仓库地址：甘肃省 ...

一、换发后的《食品生产许可证》基本信息 关于取得换发后的《食品生产许可证》的公告 生产者名称：甘肃陇神戎发药业股份有限公司 统一社会信用代码：91620000720238148G 法定代表人（负责人）：宋敏平 住所：甘肃省兰州市榆中县定远镇国防路 10 号 生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 食品类别：糖果制品，保健食品 许可证编号：SC12762012300342 有效期至：2027 年 04 月 11 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）因增加食品类别申请 变更《食品生产许可证》，于近日收到由甘肃省市场监督管理局换发后的《食品 生产许可证》，现将有关情况公告如下： 证券代码：300534 证券简称：陇神戎发 公告编号：2023-080 甘肃陇神戎发药业股份有限公司 发证机关：甘肃省市场监督管理局 二、对公司的影响 本次换发《食品生产许可证》是基于公司实际生产经营需要，公司结合市场 需求，正在开发一款将红曲与硬果糖相结合的具有保健功能的普通食品。新证的 取得有利于进一步丰富公司产 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2023-079 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）因其《药品生产许可证》中企业法 定代表人和企业负责人申请变更，于近日收到由甘肃省药品监督管理局换发登记 变更后的《药品生产许可证》，现将有关情况公告如下： 一、控股子公司换发后的《药品生产许可证》基本信息 企业名称：甘肃普安制药股份有限公司 社会信用代码：91620600762352467T 注册地址：甘肃省武威市凉州区黄羊生态工业（食品）示范园农大北路 1 号 法定代表人：康永红 分类码：AhzBzDh 日常监督管理机构：甘肃省药品监督管理局 二、本次变更对公司的影响 基于日常经营管理实际需要，普安制药申请将《药品生产许可证》中的企业 法定代表人由胡宁变更为康永红，企业负责人由宋敏平变更为康永红，依法完成 企业负责人：康永红 质量负责人：陈双明 生产地址 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥591,472,243.50, an increase of 113.94% compared to ¥276,471,418.60 in the same period last year[21]. - Net profit attributable to shareholders was ¥32,193,271.72, up 283.49% from ¥8,394,915.48 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥30,415,343.54, reflecting a 317.37% increase from ¥7,287,295.44 in the prior year[21]. - The basic earnings per share rose to ¥0.1061, a significant increase of 283.03% compared to ¥0.0277 in the same period last year[21]. - The total revenue for the first half of 2023 was CNY 318.6 million, representing a 54.0% increase compared to the same period last year[66]. - The company reported a net profit of CNY 28.5 million, which is a significant increase from the previous year's figures[66]. - The total comprehensive income for the first half of 2023 was CNY 45,481,616.87, compared to CNY 13,907,668.59 in the same period of 2022, indicating a strong performance[154]. - The company reported a net profit of 39.03 million CNY for the period, exceeding the performance commitment of 23.3 million CNY for the acquired subsidiary, Puan Pharmaceutical[105]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,303,127,658.31, showing a slight increase of 0.09% from ¥1,301,901,629.42 at the end of the previous year[21]. - The net assets attributable to shareholders were ¥602,139,756.79, which is a 5.65% increase from ¥569,946,485.07 at the end of the previous year[21]. - The total assets as of June 30, 2023, amounted to CNY 890,443,118.37, up from CNY 832,478,595.52 at the beginning of the year, reflecting a growth of approximately 6.9%[151]. - Total liabilities increased to CNY 330,499,641.14 as of June 30, 2023, compared to CNY 100,357,683.96 at the start of the year, marking a rise of about 228.5%[151]. - The company's current assets decreased to CNY 683,206,467.21 from CNY 711,935,915.16 at the beginning of the year, representing a decline of approximately 4%[145]. Cash Flow - The net cash flow from operating activities was negative at -¥17,824,771.67, a decline of 143.59% compared to a positive cash flow of ¥40,888,955.91 in the same period last year[21]. - The company reported a net cash outflow from operating activities of CNY -17,824,771.67 for the first half of 2023, compared to a net inflow of CNY 40,888,955.91 in the first half of 2022[158]. - The cash and cash equivalents decreased to ¥258,092,888.80, down 8.55% from the previous year, reflecting changes in cash flow dynamics[62]. - The total cash outflow from operating activities was CNY 156,429,336.17, which is an increase of 51% from CNY 103,751,476.39 in the previous year[160]. Market and Product Development - The company completed the acquisition of 70% equity in Puan Pharmaceutical on February 7, 2023, making it a subsidiary[34]. - The main product, Yuanhu Zhitong Dripping Pill, is a national key new product and has been included in the National Basic Medical Insurance Directory[33]. - The company is actively involved in the research and development of new products and technologies to expand its market presence[30]. - The company has established partnerships with over 1,000 distributors, including major pharmaceutical enterprises, enhancing its market reach[38]. - The company has increased its product offerings to 25 after the acquisition of Puan Pharmaceutical, with key products including the Yuanhu Zhitong Pill and Xuanfei Zhike Decoction, both of which are included in national essential drug lists[39]. Research and Development - Research and development investment increased by 61.62% to ¥14,336,590.38, indicating the company's commitment to enhancing its R&D capabilities[58]. - The company has established five R&D platforms and has received multiple technology patents, particularly in the production of traditional Chinese medicine droplet preparations[46]. - Gansu Longshen Rongfa has invested in R&D for its main product, Yuanhu Zhitong Dripping Pills, resulting in multiple patents and enhanced market competitiveness[78]. Management and Governance - The company appointed a new CFO, Zhao Zhengcai, following the resignation of the previous CFO, Liu Maosheng, due to work adjustments[55]. - The company appointed Qian Shuangxi as the new general manager on March 10, 2023, following the resignation of the previous general manager, Kang Yonghong[86]. - The company has a strong management team with over 20 years of experience in the pharmaceutical industry, enhancing its operational capabilities[50]. Risks and Challenges - The company has faced risks which are detailed in the report, and investors are advised to read the risk management section carefully[5]. - The company faces risks from national medical reform policies, which may impact drug pricing and profitability due to increased competition[77]. - Rising prices of traditional Chinese medicine materials could lead to increased production costs, prompting the company to enhance management and optimize procurement strategies[80]. Environmental and Social Responsibility - The company actively participated in rural revitalization efforts, donating winter supplies worth CNY 16,700 and planting 2,650 trees valued at CNY 20,000 in local villages[91]. - The company has a wastewater treatment facility with a design capacity of 200 tons per day, which is currently operating normally and meets discharge standards for COD and ammonia nitrogen[91]. - The company did not experience any environmental penalties during the reporting period and has implemented measures to ensure compliance with environmental regulations[91]. Shareholder Information - The total number of shares is 303,345,000, with 2,447,254 shares (0.81%) being limited sale shares and 300,897,746 shares (99.19%) being unrestricted sale shares[129]. - The largest shareholder, Gansu Pharmaceutical Investment Group Co., Ltd., holds 29.93% of the shares, totaling 90,785,250 shares[131]. - The company has not reported any changes in the number of limited sale shares during the reporting period[130].

证券代码：300534 证券简称：陇神戎发 公告编号：2023-074 甘肃陇神戎发药业股份有限公司 第四届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第四届董事会第二十 七次会议通知于 2023 年 8 月 15 日以电子邮件及电话通知方式发出，会议于 2023 年 8 月 25 日以通讯表决方式在公司六楼会议室召开。本次会议由公司董事长宋 敏平先生主持，应出席会议董事 9 人，实际出席会议董事 9 人。公司监事会成 员、高管人员列席了会议。本次会议的召集、召开符合《公司法》等有关法律、 行政法规、部门规章和《公司章程》的相关规定，合法有效。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过了《关于新增 2023 年度日常关联交易预计的议案》 二、董事会会议审议情况 1、审议通过了《关于公司<2023 年半年度报告全文>及<2023 年半年度报告 摘要>的议案》 根据公司及控股子公司甘肃普安制药股份有限公司（以下简称"普安制药"） 20 ...

甘肃陇神戎发药业股份有限公司独立董事 关于第四届董事会第二十七次会议相关事项的独立意见 二、关于新增 2023 年度日常关联交易预计的独立意见 本次新增 2023 年度日常关联交易预计事项是公司及控股子公司日常经营活 动所需。交易价格遵循公平合理的定价原则，不存在损害公司全体股东、特别是 中小股东利益的情形；不会对公司的财务状况、经营成果造成重大不利影响；不 会对公司独立性产生影响，公司董事会在审议此项议案时，关联董事已回避表决， 审议及表决程序符合相关法律法规和《公司章程》的规定，全体独立董事一致同 意本次新增关联交易预计事项。 （以下无正文） 一、关于 2023 年半年度公司控股股东及其他关联方占用公司资金、公司对 外担保情况的独立意见 李宗义： 根据中国证监会《关于规范上市公司与关联方资金往来及上市公司对外担保 若干问题的通知》（证监发[2003]56 号）和《关于规范上市公司对外担保行为的 通知》（证监发[2005]120 号）等规定和要求以及《公司章程》、《对外担保管理 制度》等规定，对公司 2023 年半年度控股股东、实际控制人及关联方占用资金、 公司对外担保情况进行了认真的了解和核查，发表如下独 ...